Evidence-based explainers, regulatory breakdowns, and research summaries — in plain language.
The FDA's advisory committee voted July 23-24, 2026. BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon received favorable recommendations. DSIP was rejected by one vote. Here's what actually happened — and what it does not mean.
Dr. Abud Bakri spent 2.5 hours on Huberman Lab walking through peptide science, safety, sourcing, and regulation. Here's a plain-language breakdown of every compound they discussed, what the evidence actually shows, and what they got right.
Eight major vendors closed. One was raided by federal agents. Two sets of founders faced criminal prosecution. Sourced from federal court records, FDA enforcement data, and independent testing — with no vendor bias.
The complete plain-language breakdown — FDA categories, what changed in February and April 2026, the July PCAC hearing, and what every researcher needs to know right now.
Seven peptides. Two days. The most significant regulatory review in peptide history. Everything you need to know about the July 23–24 PCAC hearing — including how to submit a public comment before July 9.
A plain-language breakdown of 300+ published papers on the most researched repair peptide in the compounding world.
New to peptides? Start here. What they are, how they're regulated, how to read the evidence, and where to begin your research.
Not all COAs are equal. Here's exactly what a legitimate third-party COA looks like, which labs are credible, and the red flags to watch for.
Peptides and steroids are completely different compounds. Mechanisms, legal status, risk profiles — and why the confusion keeps happening.
Ozempic is a peptide — but most peptides are nothing like Ozempic. The GLP-1 class explained, and where every other category fits.
Bloomberg Businessweek just called millions of Americans peptide curious. What the feature got right, what it missed, and the honest next step.
More guides being added regularly. Subscribe below to get them in your inbox.
